Furthermore, dual treatment with ATRA and oxaliplatin markedly potentiated anti–PD-1 efficacy in colorectal cancer models by modulating the tumor immune microenvironment and increasing CD8+ T-cell infiltration (119). Here, CD8A is linked to neoplasm.